Challenge

Gram-negative bacteria are responsible for some of the most serious infections in both animals and humans. Their potency comes from a powerful endotoxin, lipopolysaccharide (LPS), which drives inflammation, tissue damage, and disease severity.

Yet most diagnostic systems are designed to detect the bacteria itself, not the biological signal that causes the damage. As a result, infections can be missed or detected too late, even when clinical symptoms are clear. Traditional pathogen tests often return negative results, while the inflammatory cascade triggered by LPS continues unchecked.

This disconnect contributes to delayed treatment decisions, inappropriate antibiotic use, and the growing global challenge of antimicrobial resistance.

The true driver of disease has been hiding in plain sight.

Solution

Koru Biotech discovered a novel immune biomarker complex formed when LPS binds to IgG antibodies. This LPS/IgG immune complex acts as a highly specific biological signal, confirming the presence of Gram-negative infection and correlating with disease severity.

Rather than detecting pathogens alone, our approach captures the immune system’s real-time response to infection. This enables earlier, more accurate detection and more informed treatment decisions.

Peer-reviewed research and secured patents validate this discovery and provide a defensible scientific foundation for growth.

Today, Koru is advancing a research and development portfolio built on this discovery. We are focused on the rapid detection, prevention, and targeted management of infectious disease. Our initial programmes address coliform mastitis in dairy cows and enteritis in newborn calves, while the underlying platform holds broader potential across species under a One Health framework.

What began as a diagnostic insight is now a scalable biotechnology platform.